CRIA is very pleased to announce a new contract with the Westchester County Department of Health to conduct community forums on resistance testing in several areas north of New York City. As CRIA's other treatment education services, the upcoming events will be designed primarily for people living with AIDS (PLWAs) and non-medical care provider audiences. CRIA will be working cooperatively on this project with the largest HIV service provider in the targeted communities -- AIDS Related Community Services (ARCS). Our role will be to develop a curriculum for these events as well as written materials which participants can use to reinforce the subject matter discussed. We will also be responsible for securing expert speakers who can explain issues surrounding resistance testing in ways that are accessible to a lay audience. ARCS will provide outreach for participants as well as manage several key logistical functions. Call CRIA's Treatment Education Department for additional information on this new project.
Abstract to be presented at Retrovirus Conference
CRIA's researchers will be presenting results of our recent pilot independent trial of topical Acelylsalicylic Acid (aspirin) combined with Diethyl Ether in the treatment of peripheral neuropathy at February's Eighth Conference on Retroviruses and Opportunistic Infections in Chicago. CRIA Board Member Jill Cadman proposed the study to our Research Advisory Committee because so many of our patients suffer with this painful condition on a daily basis. No effective treatment has been developed to address either the root causes of peripheral neuropathy or to alleviate its symptoms. It was hoped that the topical application of aspirin would at least offer more effective relief than aspirin taken orally or other alternative existing therapies. Fortunately, the results of our trial were positive. We are naturally excited to publicize these findings to the national HIV scientific community in the hopes that care providers will begin to consider use of topical aspirin as a way to alleviate pain for many thousands of individuals who suffer with peripheral neuropathy. Look for a copy of the abstract following its presentation at the February conference to be included in the next CRIA Update as well as on our web site.
CRIA Begins New Study of Genotypic Testing
CRIA has begun working with Visible Genetics to conduct a new study of their genotypic testing product. This is our first foray into examining the potential benefits of the relatively new diagnostic tests. CRIA's protocol, called Vigilance II, has two goals. First, it will look at whether treatment outcomes for patients whose physicians use results of genotypic tests to help determine which antiretroviral drugs to prescribe differ from patients whose physicians do not utilize this information. Second, the study will allow us to develop a database that quantifies the prevalence of different HIV strains within the New York City area. Such information can possibly help physicians to prescribe regimens that are more likely to be effective from the start at suppressing HIV. Our new database would also be valuable for HIV researchers in designing innovative trials. CRIA's goal is to enroll 1,000 patients into Vigilance II over the next 12 months. Call our research department if you have any questions about this study.
CRIA Board Elections
CRIA is pleased to announce the re-election of Board Members Marisa Cardinale, Bob Colacello, Douglas Dieterich, MD, Tiffany Dubin and Renaldo Herrera at our September 20th Annual Meeting. Also, after four years on the Board, Brian Hayman decided to resign his position. CRIA's staff would like to thank all of these individuals for the commitment they have shown to our work over the past several years and the direction they will provide to us in the years to come.
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication CRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.